VetMedGuide

Vet Med Guide

Companion animal in a veterinary exam setting with medication reference materials.
Pharmaceuticals2026-06-10 · 11 min read

FIP in Cats: GS-441524 Treatment, Diagnosis, and What Owners Need to Know

GS-441524 has transformed FIP from a fatal diagnosis to a treatable condition. Here is how FIP is diagnosed, how treatment works, what it costs, and the regulatory landscape in 2026.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Feline infectious peritonitis (FIP) was one of the most devastating diagnoses a veterinarian could deliver. For decades, it was almost invariably fatal. That changed with the antiviral GS-441524, a nucleoside analogue that has shifted FIP from a death sentence to a treatable condition in many cats.

But the story is more complicated than a single breakthrough drug. Access, cost, diagnosis, and regulatory status all shape what happens after a cat is diagnosed with FIP. Here is what the evidence says in 2026 — and what owners and veterinarians should know before making treatment decisions.

What Is FIP?

FIP is caused by mutant forms of feline coronavirus (FCoV), a common virus that most cats encounter at some point. In the vast majority of cats, FCoV causes either no symptoms or mild, self-limiting diarrhea. In a small subset, the virus mutates into a form that hijacks the immune system, triggering widespread inflammation in blood vessels (vasculitis) and organs.

There are two main clinical forms:

  • Wet (effusive) FIP. Fluid accumulates in the abdomen (ascites), chest (pleural effusion), or both. This form progresses rapidly and was historically fatal within days to weeks.
  • Dry (non-effusive) FIP. Granulomatous inflammation develops in organs — kidneys, liver, eyes, central nervous system, or intestines — without significant fluid accumulation. This form progresses more slowly but is equally fatal without treatment.

Some cats present with mixed features, and the clinical picture can shift during the course of disease. Kittens and young cats (under two years) are disproportionately affected, though FIP can occur at any age. Cats from multi-cat households, shelters, and breeding catteries are at higher risk due to the prevalence of FCoV in these environments.

How FIP Is Diagnosed

FIP is notoriously difficult to definitively diagnose. There is no single blood test that confirms it, and the disease mimics many other conditions.

Clinical Suspicion

Diagnosis starts with clinical signs: persistent fever unresponsive to antibiotics, weight loss, lethargy, fluid accumulation (wet form), or granulomatous lesions in the eyes or nervous system (dry form). A cat under two years old with a fever of unknown origin and a distended abdomen is a classic FIP suspect — but FIP does not follow rules perfectly, and older cats can develop it too.

Laboratory Findings

Common blood abnormalities include:

  • Elevated total protein (hyperglobulinemia) with a low albumin-to-globulin (A:G) ratio (below 0.8 is suggestive; below 0.5 is strongly suggestive)
  • Elevated bilirubin
  • Nonregenerative anemia
  • Lymphopenia
  • Elevated inflammatory markers (serum amyloid A)

None of these are specific to FIP alone. They build clinical suspicion when taken together.

Fluid Analysis (Wet FIP)

If abdominal or thoracic fluid is present, analysis is one of the strongest non-invasive tools. FIP fluid is typically:

  • Yellow, sticky, and high in protein
  • Has a high specific gravity and high cell count (predominantly neutrophils and macrophages)
  • Fluid A:G ratio above 0.8 makes FIP unlikely; below 0.4 makes it highly likely

Rivalta's test — a simple in-clinic test using fluid and acetic acid — is highly sensitive for FIP, though not perfectly specific.

Imaging

Ultrasound can reveal abdominal effusion, enlarged mesenteric lymph nodes, irregular renal contours, and hyperechoic hepatic parenchyma. It is useful for guiding fluid sampling and evaluating organ involvement but is not diagnostic on its own.

Definitive Diagnosis

Histopathology with immunohistochemistry (IHC) staining for FCoV antigen in tissue lesions remains the gold standard for definitive diagnosis. This requires a tissue biopsy, which may not always be practical in critically ill cats.

PCR testing on fluid or tissue can detect FCoV RNA, but PCR positivity alone does not confirm FIP — many healthy cats carry enteric FCoV. The clinical context matters. Newer PCR assays that detect the mutation associated with FIP (rather than just the presence of FCoV) are more helpful but not universally available.

Empiric Treatment as a Diagnostic Tool

Because definitive diagnosis can be difficult, especially in critically ill cats, some veterinarians now use response to antiviral therapy as a practical diagnostic test. A cat with clinical and laboratory signs consistent with FIP that improves within days of starting GS-441524 is considered to have confirmed FIP. This approach is endorsed by leading feline medicine specialists and the International Cat Care treatment guidelines.

GS-441524: The Drug That Changed FIP Treatment

What It Is and How It Works

GS-441524 is a nucleoside analogue antiviral originally developed by Gilead Sciences. It is the active metabolite of remdesivir, the drug approved for human COVID-19 treatment. GS-441524 works by inserting itself into the viral RNA chain, blocking replication of the feline coronavirus.

Treatment Regimens

Current treatment protocols, based primarily on clinical trials from the UK and Australia and updated by the International Cat Care guidelines (July 2025), generally follow this structure:

  • Drug: Oral GS-441524 (preferred first-line)
  • Dose: Varies by clinical form and formulation. Current oral dosing guidelines from the 2025 International Cat Care update recommend approximately 15 mg/kg once daily for uncomplicated FIP (without ocular or neurological involvement), with higher doses (15–20 mg/kg) for ocular involvement and twice-daily dosing for neurological FIP. Older subcutaneous protocols used lower doses (2 mg/kg) because injectable formulations achieve different pharmacokinetics. Your veterinarian will determine the appropriate dose based on your cat's clinical form, weight, and response.
  • Duration: The standard protocol has been 84 days (12 weeks). However, a 2024 randomized controlled trial from Germany (Zuzzi-Krebitz et al.) demonstrated that 42 days of treatment was non-inferior to 84 days in a subset of cats, and shorter protocols are increasingly discussed in the literature. Duration decisions should be individualized and guided by a veterinarian.
  • Route: Oral tablets or suspension are now standard. Injectable formulations were used historically but have been largely replaced by oral forms.

Alternative and Adjunctive Antivirals

  • Remdesivir: The prodrug of GS-441524, converted to GS-441524 in the body. Available as an FDA-approved human drug, it can be used extra-label in cats. Used when GS-441524 is unavailable or as part of combination therapy.
  • Molnupiravir: A second-line antiviral reserved for cats failing or relapsing on GS-441524. It carries teratogenicity concerns and requires careful handling by caregivers.
  • GS-441524 + remdesivir combination: Some protocols use remdesivir injections initially for severely ill cats who cannot take oral medication, transitioning to oral GS-441524 once stable.

Adjunctive treatments include:

  • Supportive care (fluid therapy, nutritional support)
  • Anti-inflammatory medications (prednisolone may be used during early treatment)
  • Treatment of secondary infections
  • Ocular or neurological monitoring as indicated

Response to Treatment

Most cats show clinical improvement within 2–5 days of starting treatment, with obvious improvement by 1–2 weeks. Resolution of fever, improved appetite, and decreased effusion are early positive signs.

Survival rates with properly compounded, legally sourced GS-441524 exceed 85–90% in published case series, with some studies reporting rates above 90% when compliance and supportive care are optimal.

Monitoring During Treatment

Veterinarians typically monitor:

  • Clinical response (appetite, energy, weight, resolution of effusion)
  • Blood work (declining globulin, rising albumin, improving A:G ratio, resolving anemia)
  • Resolution of specific organ involvement (ocular exams, neurological assessments)

Relapse after treatment completion occurs in a minority of cats and may require retreatment at higher doses or with alternative antivirals.

Regulatory Status and Access in the United States

This is where the FIP story becomes more complex.

No FDA-Approved Drug

As of June 2026, there is no FDA-approved drug specifically for the treatment of FIP in cats. Gilead Sciences holds the patent for GS-441524 but has not pursued veterinary approval, reportedly because the company prioritized human applications during the COVID-19 pandemic.

FDA Enforcement Discretion (GFI #256)

On May 10, 2024, the FDA announced that it does not intend to enforce new animal drug approval requirements for products compounded from GS-441524 when prescribed by a veterinarian for a specific cat patient for FIP treatment, under conditions described in Guidance for Industry (GFI) #256.

This is not the same as FDA approval. Key distinctions:

  • GS-441524 compounded from bulk drug substance remains an unapproved drug.
  • The FDA is exercising enforcement discretion — choosing not to pursue regulatory action — rather than granting legal status.
  • Compounding must follow GFI #256 guidelines, including patient-specific prescriptions.
  • State regulations vary. Some states allow office-stock compounding (having the drug available before a specific patient prescription), while others do not.

Compounding Sources

In the US, compounded GS-441524 is available through:

  • Stokes Pharmacy (partnered with the Bova Group), which offers an oral formulation using the Bova GS-441524 preparation studied in peer-reviewed publications.
  • Epicur Pharma and other GFI #256-compliant compounding pharmacies that offer patient-specific formulations.

The Bova formulation used by Stokes has been studied in three peer-reviewed publications and represents the most evidence-backed compounded form available in the US.

The Black-Market Problem

Before legal compounding became available, many US cat owners obtained GS-441524 through unregulated black-market sources — often Facebook groups and underground suppliers. This was driven by genuine desperation: FIP was fatal, and an effective treatment existed but was inaccessible through normal veterinary channels.

Black-market products carry real risks:

  • Unknown and variable drug concentration
  • Contamination and impurities
  • No quality control or regulatory oversight
  • No guarantee of the actual drug being present
  • Rare reports of GS-441524 uroliths (bladder stones) associated with products containing unknown and potentially excessive levels of antiviral

The legal availability of compounded GS-441524 has significantly reduced — but not eliminated — black-market use. Some owners continue to use unregulated sources due to lower cost, and some veterinary practices still encounter clients who obtained medication outside normal channels.

Anivive and the Path to Full Approval

Anivive Lifesciences has publicly stated it is working with the FDA toward approval of an FIP treatment, but no timeline has been announced. UC Davis researchers also continue to study FIP treatment options.

What FIP Treatment Costs

Cost is one of the most difficult aspects of FIP treatment. Estimates vary widely depending on geographic location, form of FIP, duration of treatment, and whether complications arise.

Approximate ranges based on reported data:

  • Diagnostic workup: $500–$2,000 (blood work, imaging, fluid analysis, possibly biopsy)
  • GS-441524 compounded medication: $2,000–$6,000 for a typical 12-week course, depending on the cat's weight, dose required, and compounding pharmacy
  • Veterinary monitoring visits: $500–$2,000 over the treatment course
  • Hospitalization (if needed at diagnosis): $500–$3,000

Total treatment costs commonly range from $3,000 to $10,000 or more. This is a significant financial commitment, and pet insurance coverage for FIP treatment varies by provider and policy — some policies may cover diagnostics and supportive care but may not cover compounded (unapproved) medications.

When to Talk to Your Veterinarian

Contact a veterinarian promptly if your cat shows:

  • Persistent fever
  • Unexplained weight loss or decreased appetite
  • Abdominal distension or difficulty breathing
  • Eye inflammation or vision changes
  • Neurological signs (wobbly gait, seizures, behavior changes)
  • Lethargy lasting more than a few days in a young cat

FIP can progress rapidly. Earlier diagnosis and treatment are associated with better outcomes. If your veterinarian suspects FIP, ask about referral to a veterinarian experienced with FIP diagnosis and current treatment protocols.

What to Ask Your Veterinarian If FIP Is Suspected

  • What findings support the FIP diagnosis, and what else could explain these signs?
  • Is fluid analysis or additional testing needed to increase diagnostic confidence?
  • Do you have experience treating FIP with GS-441524, or should we consult a specialist?
  • What compounding pharmacies do you work with for legally sourced GS-441524?
  • What is the estimated cost for the full treatment course, including monitoring?
  • What monitoring schedule do you recommend during treatment?
  • What signs of relapse should I watch for after treatment ends?

Sources

Topics
Drug Safety & ToxicologyVaccination & Infectious Disease
Related Articles